Document:

<PAGE>

Exhbit 4.10       Collaboration Agreement, dated March 31, 2001, between
                  Gemini Genomics (UK) Limited and CuraGen Corporation

          Confidential Treatment Requested and the Redacted Material
                has been separately filed with the Commission

<PAGE>

                               DATED 23 MARCH 2001

                          GEMINI GENOMICS (UK) LIMITED

                                     - AND -

                               CURAGEN CORPORATION

                          -----------------------------
                                  COLLABORATION

                                    AGREEMENT
                          -----------------------------

                                 ARNOLD & PORTER
                                    TOWER 42
                               25 OLD BROAD STREET
                                 LONDON EC2N 1HO

                              T+44(0) 020 7786 6100
                              F+44(0) 020 7786 6299

<PAGE>

THIS AGREEMENT is made the 23d day of March 2001

BETWEEN:

(1)     GEMINI GENOMICS (UK) LIMITED whose principal place of business is at 162
        Science Park, Milton Road, Cambridge, C134 4GH ("Gemini"); and

(2)     CURAGEN CORPORATION whose principal place of business is at 555 Long
        Wharf Drive, New Haven, CT USA ("CuraGen").

WHEREAS:

(A)     Gemini and CuraGen wish to collaborate in a research programme with the
        aim of genotyping certain DNA Samples (as defined herein).

(B)     In connection with such collaborative research programme it is
        contemplated that Gemini shall provide the DNA Samples. It is further
        contemplated that CuraGen shall fund the work to be conducted by Gemini
        under the research programme.

(C)     CuraGen shall have the responsibility for commercialising the results of
        the research programme (which results shall be owned by Gemini and
        licensed to CuraGen on the terms set out herein.)

DEFINITIONS

1.1     In this Agreement the following definitions shall apply unless the
        context requires otherwise:

        1.1.1   "AFFILIATE" - any company, partnership or other business entity
                which Controls, is Controlled by or is under common Control with
                either Party;

        1.1.2   "AGREEMENT" - this document including any and all schedules,
                appendices and other addenda to it as may be added and/or
                amended from time to time in accordance with the provisions of
                this Agreement;

        1.1.3   "BUSINESS DAY" - a day other than a Saturday, Sunday, bank or
                other public holiday in England and Wales or the USA;

        1.1.4   "CLINICAL DATA" - the phenotypic data in Gemini's possession and
                control relating to the LTLSAM Samples and provided to CuraGen
                pursuant to Clause 2. 1, including, without limitation, the data
                described on Schedule 3 attached hereto.

        1.1.5   "COMMENCEMENT DATE" - the date of execution of this Agreement by
                the Parties;

        1.1.6   "COMPETENT AUTHORITY" - any national or local agency, authority,
                department, inspectorate, minister, ministry official,
                parliament or public or statutory person (whether autonomous or
                not) of any government of any country having jurisdiction over
                either any of the activities contemplated by this Agreement or
                over the Parties, including the European Commission, The Court
                of First Instance and the European Court of Justice.

                                      -2-
<PAGE>

        1.1.7   "COMPLETED GENOTYPES" - a [***] genotype for a unique marker
                individual combination, except in the case of [***] genotypes in
                male subjects where there is [***].

        1.1.8   "CONFIDENTIAL INFORMATION" - in the case of obligations of
                Gemini in relation to Confidential Information shall mean
                CuraGen Technology and, in the case of obligations on CuraGen in
                relation to Confidential Information, shall mean Gemini
                Technology and, in the case of both Gemini and CuraGen, shall
                mean all data generated by either or both Parties hereunder and
                trade secrets and/or confidential information relating to
                technology and/or relating to the business affairs not limited
                to commercial forecasts, plans, programs, customers, assets,
                financial projections, costs and customer lists and/or finances
                of a Disclosing Party supplied or otherwise made available to
                the Recipient Party or coming into the Recipient Party's
                possession in relation to the performance of this Agreement;

        1.1.9   "CONTROL" - means the ownership either directly or indirectly of
                more than 50% of the issued share capital or any other
                comparable equity or ownership interest with respect to a
                business entity or the legal power to direct or cause the
                direction of the general management and policies of the Party in
                question;

        1.1.10  "CURAGEN KNOW-HOW" - all Know-How necessary and directly
                applicable to the conduct of the Research Programme and which is
                owned by or licensed (with a right to sub-license) to CuraGen as
                at the Commencement Date or during the term of the Research
                Programme and provided by CuraGen for use in the conduct of the
                Research Programme;

        1.1.11  "CURAGEN PATENT RIGHTS" - the Patent Rights which claim CuraGen
                Know How and which are owned by or licensed (with rights to
                sub-license) to CuraGen at the Commencement Date or during the
                term of this Agreement and which would, but for the grant of a
                licence hereunder, be infringed by the conduct of the Research
                Programme;

        1.1.12  "CURAGEN TECHNOLOGY" - CuraGen Know How and CuraGen Patent
                Rights;

        1.1.13  "DISCLOSING PARTY" - the Party which discloses Confidential
                Information to the other Party;

        1.1.14  "DNA SAMPLES" - those clinical samples of human DNA in Gemini's
                possession and control.

                                      -3-
<PAGE>

        1.1.15  "DOCUMENTS" - reports, research notes, charts, graphs, comments,
                computations, analyses, recordings, photographs, paper,
                notebooks, books, files, ledgers, records, tapes, discs,
                diskettes, CD-ROM, computer programs and documents thereof,
                computer information storage means, samples of material, other
                graphic or written data and any other media on which Know How
                can be permanently stored;

        1.1.16  "FDA" - the United States Food and Drug Administration or any
                successor agency thereto or the equivalent Competent Authority
                or Regulatory Authority in any other country;

        1.1.17  "FORCE MAJEURE" - in relation to either Party, any event or
                circumstance which is beyond the reasonable control of that
                Party which event or circumstance that Party could not
                reasonably be expected to have taken into account at the date of
                this Agreement and which results in or causes the failure of
                that Party to perform any or all of its obligations under this
                Agreement including acts of God, lightning, fire, storm, flood,
                earthquake, accumulation of snow or ice, lack of water arising
                from weather or environmental problems, strike, lockout or other
                industrial or student disturbance, act of the public enemy, war
                declared or undeclared, threat of war, terrorist act, blockade,
                revolution, riot, insurrection, civil commotion, public
                demonstration, sabotage, act of vandalism, prevention from or
                hindrance in obtaining in any way materials, energy or other
                supplies, explosion, fault or failure of plant or machinery
                (which could not have been prevented by good industry practice),
                or Legal Requirement governing either Party, provided that lack
                of funds shall not be interpreted as a cause beyond the
                reasonable control of that Party;

        1.1.18  "GERNINI KNOW HOW" - all Know How necessary and directly
                applicable to the conduct of the Research Programme and which is
                owned by or licensed (with rights to sub-license) to Gemini as
                at the Commencement Date or during the term of the Research
                Programme.

        1.1.19  "GENIINI PATENT RIGHTS" - all Patent Rights which claim Gemini
                Know How and which are owned by or licensed (with rights to
                sub-license) to Gemini as at the Commencement Date or during the
                term of the Research Programme and which would, but for the
                grant of a licence hereunder, be infringed by the conduct of the
                Research Programme.

        1.1.20  "GENDNI TECHNOLOGY" - Gemini Know How and Gemini Patent Rights.

        1.1.21  "GENOTYPING" - the creation of Completed Genotypes.

                                      -4-
<PAGE>

        1.1.22  "INSOLVENCY EVENT" - in relation to either Party, means any one
                of the following:

                (a)    a notice shall have been issued to convene a meeting for
                       the purpose of passing a resolution to wind up that
                       Party, or such a resolution shall have been passed other
                       than a resolution for the solvent reconstruction or
                       reorganisation of that Party or for the purpose of
                       inclusion of any part of the share capital of that Party
                       in the Official List of the London Stock Exchange or in
                       the list of the American Stock Exchange or quotation of
                       the same on the National Association of Securities
                       Dealers Automated Quotation System; or

               (b)     a resolution shall have been passed by that Party's
                       directors to seek a winding up, or an administration
                       order or a petition for a winding up or administration
                       order shall have been presented against that Party or
                       such an order shall have been made; or

               (c)     a receiver, administrative receiver, receiver and
                       manager, interim receiver, custodian, sequestrator or
                       similar officer is appointed in respect of that Party or
                       over a substantial part of its assets or any third party
                       takes steps to appoint such an officer in respect of that
                       Party or an encumbrancer takes steps to enforce or
                       enforces its security; or

               (d)     a proposal for a voluntary arrangement shall have been
                       made in relation to that Party under Part I Insolvency
                       Act 1986; or

               (e)     a step or event shall have been taken or arisen outside
                       the United Kingdom which is similar or analogous to any
                       of the steps or events listed at (a) to (d) above; or

               (f)     that Party takes any step outside the ordinary course of
                       business (including starting negotiations) with a view to
                       readjustment, rescheduling or deferral of any part of
                       that Party's indebtedness, or proposes or makes any
                       general assignment, composition or arrangement with or
                       for the benefit of all or some of that Party's creditors
                       or makes or suspends or threatens to suspend making
                       payments to all or some of that Party's creditors or the
                       Party submits to any type of voluntary arrangement; or

               (g)     where that Party is resident in the United Kingdom it is
                       deemed to be unable to pay its debts within the meaning
                       of Section 123 Insolvency Act 1986;

        1.1.23  "KNOW HOW" - unpatented technical and other information which is
                not in the public domain, including information comprising or
                relating to concepts, discoveries, data, designs, formulae,
                ideas, inventions, methods, models, assays, research plans,
                procedures, designs for experiments and tests and results of
                experimentation and testing (including results of research or
                development), processes (including manufacturing processes,
                specifications and techniques), laboratory records, chemical,
                pharmacological, toxicological, clinical, analytical and quality
                control data, trial data, case report forms, data analyses,
                reports,

                                      -5-
<PAGE>

                manufacturing data or summaries and information contained in
                submissions to and information from ethical committees and
                regulatory authorities. Know How includes Documents containing
                Know How, including but not limited to any rights including
                trade secrets, copyright, database or design rights protecting
                such Know How. The fact that an item is known to the public
                shall not be taken to preclude the possibility that a
                compilation including the item, and/or a development relating
                to the item, is not known to the public;

        1.1.24  "LEGAL REQUIREMENT" - any present or future law, regulation,
                directive, instruction, direction or rule of any Competent
                Authority or Regulatory Authority inluding any amendment,
                extension or replacement thereof which is from time to time in
                force;

        1.1.25  "MARKETING AUTHORISATION" - any and all approvals required from
                a Regulatory Authority to market and sell Product in any country
                any product commercialized by CuraGen pursuant to Section 5;

        1.1.26  "MATERIAL" - any chemical or biological substance including any:

               (a)     organic or inorganic element;

               (b)     nucleotide or nucleotide sequence including DNA and RNA
                       sequences;

               (c)     gene;

               (d)     vector or construct including plasmids, phages or
                       viruses;

               (e)     host organism including bacteria, fungi, algae, protozoa
                       and hybridomas;

               (f)     eukaryotic or prokaryotic cell line or expression system
                       or any development strain or product of that cell line or
                       expression system;

               (g)     protein including any peptide or amino acid sequence,
                       enzyme, antibody or protein conferring targeting
                       properties and any fragment of a protein or a peptide
                       enzyme or antibody;

               (h)     drug or pro-drug;

               (i)     assay or reagent;

               (j)     any other genetic or biological material or
                       micro-organism;

               (k)     data for the derivation of molecular structures including
                       NMR spectra, X Ray diffraction patterns and other primary
                       experimental information, assignments and other
                       calculations required for determination of the structure
                       and coordinates of the derived molecular structure;

                                      -6-
<PAGE>

               (l)     computer programs or algorithms; and

               (m)     transgenic animals;

        1.1.27  "PARTY" - Gemini and CuraGen and "PARTIES" shall mean both of
                them;

        1.1.28  "PATENT RIGHTS" - patent applications and patents, utility
                certificates, improvement patents and models and certificates of
                addition and all foreign counterparts of them in all countries,
                including any divisional applications and patents, refilling,
                renewals, continuations, continuations-in-part, patents of
                addition, extensions, (including patent term extensions,)
                reissues, substitutions, confirmations, registrations,
                revalidations, pipeline and administrative protections and
                additions, and any equivalents of the foregoing in any and all
                countries of or to any of them, as well as any supplementary
                protection certificates and equivalent protection rights in
                respect of any of them;

        1.1.29  "QUARTER" - each period of three months ending on 31 March, 30
                June, 30 September or 31 December and "QUARTERLY" shall be
                construed accordingly;

        1.1.30  "RECIPIENT PARTY" - the Party which receives Confidential
                Information from the other Party;

        1.1.31  "REGULATORY AUTHORITY" - shall mean any national, supranational
                (e.g., the European Commission, the Council of the European
                Union, the European Agency for the Evaluation of Medicinal
                Products), regional, state or local regulatory agency,
                department, bureau, commission, council or other governmental
                entity, including the FDA, in each country involved in the
                granting of Marketing Authorisation for any product
                commercialized by CuraGen pursuant to Section 5;

        1.1.32  "RESEARCH PROGRAMME" - the programme of work set out in Schedule
                I to be conducted by Gemini and CuraGen which may be amended
                from time to time by agreement of the Parties;

        1.1.33  "RESEARCH PROGRAMME RESULTS" - any and all Patent Rights, Know
                How and Materials arising pursuant to the Research Programme;

        1.1.34  "ULSAM SAMPLES" - the [***] of each of the DNA Samples derived
                from [***] subjects which have participated in the ULSAM
                longitudinal study; and

        1.1.35  "YEAR" - twelve (12) months commencing on I January and ending
                on 31 December.

                                      -7-
<PAGE>

2.      THE RESEARCH PROGRAMME

2.1     Gemini's responsibilities under the Research Programme shall be to
        conduct Genotyping on the ULSAM Samples as set out in more detail in
        Schedule 1. Gemini shall also provide CuraGen with the Clinical Data
        associated with the ULSAM Samples within [***] of the Commencement Date.

2.2     Gemini shall carry out work under the Research Programme with all
        reasonable skill and care and in accordance with all applicable laws,
        governmental regulations and guidelines.

2.3     Gemini shall keep or cause to be kept detailed written laboratory
        notebooks and other records and reports of the progress of its part of
        the Research Programme in sufficient detail and in good scientific
        manner for all purposes including patent purposes, especially in
        accordance with practice within the USA. Such notebooks and other
        records must properly reflect all work done on the Research Programme
        and the results achieved thereunder. Upon request by CuraGen and at
        CuraGen's expense, Gemini shall provide CuraGen with copies of all such
        materials.

2.4     Gemini shall provide CuraGen with a quarterly written report on the
        progress of the Research Programme.

2.5     Gemini shall conduct the Research Programme at the Gemini Genomics AB
        site in Sweden, or, upon written notice to CuraGen, at such other site
        as Gemini may elect.

2.6     Not less than quarterly and at any time upon CuraGen's written request,
        Gemini shall provide to CuraGen copies of any and all Research Programme
        Results.

2.7     Gemini's performance of the Research Programme shall be on a
        non-exclusive basis and Gemini shall be free to conduct work the same as
        or similar to its work under the Research Programme in relation to any
        DNA Samples (including the ULSAM Samples) for any third party(ies).

2.8     Gemini may from time to time sub-contract the performance of some or all
        of its responsibilities under the Research Programme to Affiliates or
        third parties provided always that Gemini shall remain responsible for
        ensuring that its obligations hereunder are complied with in accordance
        with the terms of this Agreement; and, provided, further, that Gemini
        first notifies CuraGen of each such third party subcontract.

2.9     Gemini shall not be required to conduct more than [***] Completed
        Genotypes per Quarter as part of the Research Programme.

3.      INTELLECTUAL PROPERTY

3.1     The CuraGen Technology is and shall remain vested in CuraGen.

3.2     The Gemini Technology is and shall remain vested in Gemini.

                                      -8-
<PAGE>

3.3     CuraGen shall not use any Gemini Technology for any purpose other than
        the performance of the Research Programme.

3.4     Gemini shall not use any CuraGen Technology for any purpose other than
        the performance of the Research Programme.

3.5     The Research Programme Results shall vest in and be owned by Gemini and
        CuraGen shall at the request of Gemini execute all documents and do all
        other acts and things as may be reasonably required in order to vest
        fully and effectively all Research Programme Results in Gemini.

4.      INTELLECTUAL PROPERTY - RIGHTS AND LICENCES; PATENT PROSECUTION

4.1     During the term of this Agreement, CuraGen hereby grants to Gemini a
        nonexclusive, worldwide licence under the CuraGen Technology to use the
        same as maybe necessary solely in connection with Gemini's conduct of
        the Research Programme. Gemini may sublicense the license granted to it
        in this Section 4.1 to any third party to whom it subcontracts its
        responsibilities under Section 2.8.

4.2     Gemini hereby grants to CuraGen a non-exclusive, worldwide, royalty-free
        licence under the Gemini Technology to use the same as may be necessary
        solely in connection with CuraGen's conduct of the Research Programme.

4.3     Gemini hereby grants to CuraGen an exclusive, world-wide,
        royalty-bearing licence under the Research Programme Results to use the
        same for any and all research and commercial purposes.

4.4     Gemini, by selecting counsel to whom CuraGen has no reasonable
        objection, may, but shall not be obliged to prepare, file and prosecute,
        at its sole expense, patent applications claiming all patentable
        Research Programme Results. In connection therewith, Gemini agrees to
        provide CuraGen with a copy of such patent applications in a timely
        manner for CuraGen's review and comment prior to the first filing
        thereof and forward to CuraGen in a timely manner, a copy of all
        correspondence concerning the prosecution of such patent application(s).
        If Gemini elects not to file or thereafter prosecute any patents or
        patent applications claiming Research Programme Results in any country,
        CuraGen, will have the right to file and prosecute such patent
        application and/or maintain such patent in such country, at its sole
        expense.

5.      FINANCING OF RESEARCH PROGRAMME AND REVENUE SHARING

5.1     In consideration of Gemini carrying out its responsibilities under the
        Research Programme, CuraGen shall pay the costs incurred by Gemini
        Quarterly in arrears in conducting such work within fourteen (14) days
        of receipt of an appropriately detailed invoice from Gemini. For the
        avoidance of doubt, such costs shall not exceed [***] per Completed
        Genotype.

                                      -9-
<PAGE>

5.2      In consideration of the grant of the licence by Gemini to CuraGen
         pursuant to Clause 4.3, CuraGen shall pay to Gemini an advance royalty
         on net sales of product comprising the Research Programme Results in
         the amount of [***]. Such sum shall be payable on or before 31 March
         2001. Upon receipt by Gemini of such payment, the licence set out in
         Clause 4.3 shall become fully paid up and no further payments shall be
         due from CuraGen to Gemini in relation to such licence.

6.      WARRANTIES AND LIABILITY

6.1     Each Party represents and warrants to the other Party that:

        6.1.1          it has legal power, authority and right to enter into
                       this Agreement and to perform its respective obligations
                       in this Agreement; and

        6.1.2          it is not at the Commencement Date a party to any
                       agreement, arrangement or understanding with any third
                       party which in any significant way prevents it from
                       fulfilling any of its material obligations under the
                       terms of this Agreement.

6.2     Gemini hereby represents and warrants to CuraGen:

        6.2.1   that the Clinical Data contains the information on Schedule 3
                for each patient providing DNA Samples andthat it has obtained,
                and will continue to obtain, informed consent from all patients
                and human subject volunteers that provide Clinical Data and
                materials and/or samples comprising the DNA Samples.

        6.2.2   Neither Party shall be liable to the other in contract, tort,
                negligence, breach of statutory duty or otherwise for any
                economic loss or other loss of turnover, profits, business or
                goodwill or any loss, damage, costs or expenses of any nature
                whatsoever incurred or suffered by the other or its Affiliates
                of an indirect or consequential nature arising out of or in
                connection with this Agreement.

7.      CONFIDENTIALITY

7.1     Each of the Parties undertakes and agrees to:

        7.1.1   keep the Confidential Information confidential and not to
                disclose it to any third party without the other Party's prior
                written consent;

        7.1.2   only use the Confidential Information for the purposes envisaged
                under this Agreement and not to use the same for any other
                purpose whatsoever;

        7.1.3   ensure that only those of its officers, consultants, employees
                (including without limitation directors), sub-licensees,
                Affiliates and such third parties who are directly concerned
                with the carrying out of this Agreement have access to the
                Confidential Information on a strictly applied "need to know"
                basis and are informed of the secret and confidential nature of
                it;

                                      -10-
<PAGE>

        7.1.4   keep the Confidential Information secret and confidential and
                not directly or indirectly to disclose or permit to be
                disclosed, make available or permit to be made available the
                same to any third party for any reason without the prior written
                consent of the Disclosing Party;

        7.1.5   keep the Confidential Information separately identifiable at all
                times from all other Know How which it may hold; and

        7.1.6   clearly identify the Confidential Information as confidential.

7.2     The obligations of confidentiality referred to in Clause 7.1 shall not
        extend to any Confidential Information which:

        7.2.1   is or becomes generally available to the public otherwise than
                by reason of breach by a Recipient Party of the provisions of
                that Clause; or

        7.2.2   is known to the Recipient Party and is at its free disposal on
                the presentation of competent proof (having been or which may be
                generated independently by the Recipient Party or a third party
                in circumstances where it can be shown that it has not been
                derived from access to the Disclosing Party's Confidential
                Information); or

        7.2.3   is subsequently disclosed to the Recipient Party on the
                presentation of competent proof without obligations of
                confidentiality by a third party owing no such obligations to
                the Disclosing Party in respect of that Confidential
                Information; or

        7.2.4   is required by law to be disclosed (including as part of any
                regulatory submission or approval process) and then only when
                prompt written notice of this requirement has been given to the
                Disclosing Party so that it may, if so advised, seek appropriate
                relief to prevent such disclosure provided always that in such
                circumstances such disclosure shall be only to the extent so
                required and shall be subject to prior consultation with the
                Disclosing Party with a view to agreeing timing and content of
                such disclosure.

7.3     All Confidential Information disclosed by the Disclosing Party to the
        Recipient Party shall remain the property of the Disclosing Party. In
        the event that a court or Competent Authority assumes partial or
        complete control over the assets of a Recipient Party based on the
        insolvency or bankruptcy of that Party, the Recipient Party shall:

        7.3.1   promptly notify such court or Competent Authority that
                Confidential Information received from the Disclosing Party
                under

               (a)     this Agreement remains the property of the Disclosing
                       Party; and

               (b)     of the confidentiality obligations under this Agreement;
                       and

        7.3.2   to the extent permitted by law, take all steps necessary or
                desirable to maintain the confidentiality and security of the
                Disclosing Party's Confidential Information and to ensure that
                the court or Competent Authority maintains that Confidential
                Information in confidence in accordance with this Agreement.

                                      -11-
<PAGE>

        7.4     The Parties understand that remedies in damages may be
                inadequate to protect against any breach of any of the
                provisions of this Clause 7 by either Party or their employees,
                officers or any other person acting in concert with it or on its
                behalf. Accordingly, each Party shall be entitled to seek the
                granting of interim and final injunctive relief by a court of
                competent jurisdiction in the discretion of that court against
                any action that constitutes any breach of this Clause 7.

        7.5     The Parties agree that the obligations of confidentiality set
                out in this Clause 7 shall continue to apply for ten (10) years
                following the expiry or termination of this Agreement under
                Clause 8.

8.      TERM AND TERMINATION

  8.1    The Research Programme shall have a term of 3 years from the
         Commencement Date unless extended by agreement of the Parties.

  8.2    This Agreement shall commence on the Commencement Date and shall
         continue in force until no payments are due hereunder or until
         termination under this Clause 8 which ever is the earlier.

  8.3    Each of the Parties (the "Terminating Party") shall have the right to
         terminate this Agreement for cause upon giving written notice of
         termination to the other (the"Defaulting Party") upon the occurrence of
         any of the following events at any time during this Agreement.

        8.3.1   the Defaulting Party commits a material breach of this Agreement
                which in the case of a breach capable of remedy shall not have
                been remedied within sixty (60) days of the receipt by it of a
                written notice from the other Party identifying the breach and
                requiring its remedy;

        8.3.2   if an Insolvency Event occurs in relation to the Defaulting
                Party; and in any event, when a Party first becomes aware of the
                likely occurrence of any Insolvency Event in regard to that
                Party, it shall promptly so notify the other Party. in
                sufficient time to give the other Party sufficient notice to
                protect its interests under this Agreement.

8.4     This Agreement shall terminate immediately (i) if the material breach
        under Article 8.3.1 is incapable of remedy; (ii) after the sixty (60)
        day period permitted under Clause 8.3.1 if the Defaulting Party has
        failed to remedy the material breach which is capable of being remedied;
        or (iii) upon the giving of any notice under Clause 8.3.2.

9.      CONSEQUENCES OF TERMINATION

9.1     Upon a termination of this Agreement for any reason other than by Gemini
        for an uncured breach by CuraGen pursuant to Clause 8.3.1 (which the
        Parties agree shall not minate the provisions of this Agreement
        expressed to survive its termination) the licence set out in Clause 4.3
        shall continue in full force and effect.

10.     ASSIGNMENT/SUB-CONTRACTING

                                      -12-
<PAGE>

10.1    This Agreement and the licenses herein granted shall be binding upon and
        inure to the benefit of the successors in interest of the respective
        parties. Neither this Agreement nor any interest hereunder shall be
        assignable by either party without the written consent of the other,
        such consent not to be unreasonably withheld, provided, however, that
        either party may assign this Agreement or any part of its rights and
        obligations hereunder to any Affiliate or to any corporation with which
        such party may merge or consolidate, or to which it may transfer all or
        substantially all of its assets to which this Agreement relates, without
        obtaining the consent of the other party.

11.     MISCELLANEOUS

11.1    Neither Party shall subcontract the performance of any of its
        obligations hereunder except as expressly provided herein.

11.2    If a Party is unable to perform any of its obligations under this
        Agreement due to an event of Force Majeure, such Party shall be excused
        such performance (but only such performance) during the period of such
        Force Majeure event.

11.3    The validity, construction and interpretation of this Agreement and any
        determination of the performance which it requires shall be governed by
        English law. All disputes between the Parties arising out of the
        circumstances and relationships contemplated by this Agreement including
        disputes relating to the validity, construction or interpretation of
        this Agreement, and including disputes relating to pre-contractual
        representations which result in any action or proceedings, shall be
        subject to the exclusive jurisdiction of the English Courts.

11.4    Except as expressly provided in this Agreement nothing herein deprives
        either party or constitutes a waiver by either Party of any of its
        rights or remedies under common law, statute or otherwise.

11.5    This Agreement constitutes the entire agreement and understanding
        between the Parties and supersedes all prior oral or written
        understandings, arrangements, representations or agreements between them
        relating to the subject matter of this Agreement provided that this does
        not remove any right of action by either Party in respect of any
        fraudulent misrepresentation, fraudulent concealment or other fraudulent
        action.

11.6    All formal notices to be given pursuant to this agreement shall be in
        writing and shall be delivered by hand, post or facsimile to the address
        of the Parties set out above (or such other address as may be notified
        by a Party to the other from time to time in accordance with this
        Clause) and in the case of a facsimile with a confirmation copy being
        sent by post. Notices shall be deemed to have been received:

        11.6.1  if delivered by courier, at the time of delivery;

        11.6.2  if sent by post:

               (a)     where posted in the country of the addressee, on the
                       second working day following the day of posting; and

                                      -13-
<PAGE>

               (b)     where posted in any other country, on the fifth working
                       day following the day of posting;

        11.6.3  if sent by facsimile, on acknowledgement by the recipient
                facsimile receiving equipment on a Business Day if the
                acknowledgement occurs before 1700 hours local time on a
                Business Day of the recipient and in any other case on the
                following Business Day.

11.7    The activities of the Parties contemplated pursuant to this Agreement
        shall not constitute a partnership and neither Party is the agent of the
        other Party or has the authority to bind the other Party in any way
        except as provided in this Agreement.

11.8    Each Party shall bear its own legal costs and other expenses incurred in
        the negotiation, preparation, execution and implementation of this
        Agreement.

11.9    Any press releases to be made by either Party relating to this Agreement
        will require the approval of the other Party.

11.10   This Agreement may be executed in any number of counterparts and by the
        Parties by separate counterparts, each of which when so executed shall
        be an original and all of which shall constitute one and the same
        instrument.

11.11   The operation of the Contract (Rights of Third Parties) Act 1999 is
        hereby expressly excluded save that the Parties acknowledge and agree
        that Affiliates of either Party may enforce against the Parties (and a
        person who is the lawful successor to or a permitted assignee of the
        rights of a Party) the rights and benefits under this Agreement in
        accordance with that Act.

IN WITNESS WHEREOF the Parties have executed this agreement the day and year
first above written.

SIGNED by
for and on behalf of
GEMINI GENOMICS (UK) LTD

SIGNED by
for and on behalf of
CURAGEN CORPORATION

                                      -14-
<PAGE>

                                   SCHEDULE 1

                               RESEARCH PROGRAMME

CuraGen will provide sequence information sufficient to uniquely identify Single
Nucleotide Polymorphisms in genes of interest and oligonucleotide primers
required for genotyping each Single Nucleotide Polymorphism.

Gemini will complete individual genotyping of the ULSAM samples. Gemini will
provide data to CuraGen in [***] for further analysis.

If CuraGen requests that pooled genotyping be utilized in the Research
Programme, Gemini will use commercially reasonable efforts to do so. For pooled
genotyping, a Completed Genotype will be a completed marker-pool combination. In
no such event will Gemini be required to use more than [***] of each of the
LTLSAM Samples.

                                      -15-
<PAGE>

                                   SCHEDULE 2

                                     NOTICES

GEMINI GENOMICS (UK) LIMITED

162 Science Park,
Milton Road,
Cambridge CB44GH

CURAGEN CORPORATION

555 Long wharf Drive,
New Haven, CT USA

                                      -16-
<PAGE>

                                   SCHEDULE 3

                                  CLINICAL DATA

The table summarises [***] including codes referring to the master data set. For
[***], short descriptions are included. For some diagnoses, number of cases are
reported.

[***]

                                      -17-Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

EXHIBIT 10.1  

 
 

PURCHASE AGREEMENT    
  

    THIS PURCHASE AGREEMENT is made and entered into as of May 9, 2001 by and between Cerus Corporation, a Delaware corporation (the
"Company") and the purchaser whose name and address is set forth on the signature page hereof (the
"Purchaser"). 

    1.  Authorization and Sale of the Shares. Subject to the terms and conditions of this Agreement, the Company has
authorized the issuance and sale of up to 1,000,000 shares (the "Shares") of its common stock (the "Common
Stock"). 

    2.  Agreements to Sell and Purchase. On the basis of the representations and warranties contained in this Agreement, and
subject to its terms and conditions, the Company hereby agrees to sell to the Purchaser, and the Purchaser hereby agrees to purchase from the Company, the number of Shares set forth on the signature
page hereto at the purchase price set forth on such signature page (the "Purchase Price"). 

    3.  Payment and Delivery. Payment for the Shares shall be made to the Company in Federal or other funds immediately
available in New York City against delivery of such Shares (such payment and delivery hereinafter referred to as the "Closing") at 10:00 a.m., New York City time, on May 14, 2001, or at
such other time on the same or such other date, not later than May 14, 2001, as shall be agreed by the Company and the Purchaser. The time and date of such payment are hereinafter referred to
as the "Closing Date." Payment for the Shares shall be made by wire transfer of immediately available funds to such account or accounts specified by the
Company. 

    Certificates
for the Shares shall be registered in the name of the Purchaser or if so indicated on the signature page hereto, in the name of a nominee designated by the Purchaser. The
certificates evidencing the Shares shall be delivered to the Purchaser on the Closing Date, with any transfer taxes payable in connection with the transfer of the Shares to the Purchaser duly paid,
against payment of the Purchase Price therefor. 

    4.  Conditions to the Company's Obligations. The Company's obligation to issue and sell the Shares to the Purchaser is
subject to the following conditions: 

    (a) receipt
by the Company of Federal or other immediately available funds in the full amount of the Purchase Price; and 

    (b) accuracy
of the representations and warranties made by the Purchaser and the fulfillment in all material respects of those undertakings of the Purchaser to be
fulfilled prior to the Closing. 

    5.  Conditions to the Purchaser's Obligations. The obligations of the Purchaser to purchase and pay for the Shares on
the Closing Date are subject to the following conditions: 

    (a) The
Purchaser shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the Company, to the effect that
the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all
of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. 

The
officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened. 

    (b) The
Purchaser shall have received on the Closing Date an opinion of Cooley Godward LLP, counsel for the Company, dated the Closing Date, to the effect set forth in
Exhibit A. Such opinion shall be rendered to the Purchaser at the request of the Company and shall so state therein. 

    (c) All
corporate and other proceedings in connection with the transactions contemplated at the Closing hereby, and all documents and instruments incident to such
transactions, shall be reasonably satisfactory in substance to the Purchaser and its counsel. 

    (d) No stockholder of the Company shall have any right (which has not been effectively waived) to require the Company to register the sale of any shares owned by such
stockholder under the Securities Act in the Registration Statement (as defined in Section 8(a)) to be filed by the Company on behalf of the Purchaser pursuant to Section 8(a). 

    6.  Representations, Warranties and Covenants of the Company. The Company represents and warrants to, and covenants
with, the Purchaser that as of the date of this Agreement: 

    (a) The
Company has filed with the Securities and Exchange Commission (the "Commission") all documents required to be
filed pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act") during the 12 months preceding the date of this Agreement.
The following documents (collectively, the "Exchange Act Documents") complied when filed in all material respects with the Exchange Act and the
applicable rules and regulations of the Commission thereunder, and did not, when so filed, contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading: 

     (i) each
of the Quarterly Reports on Form 10-Q filed subsequent to the Annual Report on Form 10-K referred to in
(ii) below; 

    (ii) Annual
Report on Form 10-K for the Year Ended December 31, 2000; 

    (iii) Definitive
Proxy Statement filed with the Commission on April 18, 2001; and 

    (iv) All
other documents, if any, filed by the Company with the Commission since December 31, 2000. 

    (b) The
Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of Delaware, has the corporate power and authority to
own its property and to conduct its business as currently conducted and as described in the Exchange Act Documents and is duly qualified to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a material adverse effect on the Company. 

    (c) The
Company does not own or control, directly or indirectly, any interest in any other corporation, association or other business entity. 

    (d) This
Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms,
subject to applicable bankruptcy, insolvency or similar laws affecting creditors' rights generally and general principles of equity and except as rights to indemnification and contribution in
Section 11 hereof may be limited under applicable law. 

    (e) The
authorized capital stock of the Company conforms as to legal matters to the description (i) of the Common Stock contained in the Company's registration
statement on Form 8-A, filed with the Commission on January 8, 1997 and (ii) of the preferred stock contained in the certificates of designation filed with the
Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998. 

    (g) The
shares of common stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable. 

    (h) The
Shares have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and
non-assessable, and the issuance of such Shares will not be subject to any preemptive or similar rights. 

    (i)  The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene any provision of
applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding upon the Company that is material to the Company, except where the
contravention of such agreement or other instrument (other than the certificate of incorporation or the bylaws) 

would not have a material adverse effect on the Company, or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company, and no consent, approval,
authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may be required
by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares and by Federal and state securities laws with respect to the Company's obligations under
Sections 8 and 10 of this Agreement. 

    (j)  There
has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise,
or in the earnings, business or operations of the Company, taken as a whole, since December 31, 2000. 

    (k) There
are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company is a party or to which any of the
properties of the Company is subject other than proceedings accurately described in all material respects in the Exchange Act Documents and proceedings that would not have a material adverse effect on
the Company, or on the power or ability of the Company to perform its obligations under this Agreement to consummate the transactions contemplated by this Agreement. 

    (l)  The
Company (i) is in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human
health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants ("Environmental Laws"), (ii) has
received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its business and (iii) is in compliance with all terms and conditions of any such
permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and
conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a material adverse effect on the Company. 

    (m) To
the best of the Company's knowledge, costs and liabilities, if any, associated with its compliance with Environmental Laws as currently in effect (including,
without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related
constraints on operating activities and any potential liabilities to third parties) would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company. 

    (n) The
Company owns or possesses adequate licenses or other rights to use all patents, copyrights, trademarks, service marks, trade names, technology and
know-how necessary (in any material respect) to conduct its business in the manner described in the Exchange Act Documents; and, except as disclosed in the Exchange Act Documents, the
Company has not received any notice of infringement or conflict with (and the Company does not know of any infringement or conflict with) asserted rights of others with respect to any patents,
copyrights, trademarks, service marks, trade names, technology or know-how which could reasonably be expected to result in a material adverse effect on the Company. 

    (o) The
Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof will not be, required to register as,
an "investment company" as such term are defined in the Investment Company Act of 1940, as amended. 

    (p) Neither
the Company nor any affiliate (as defined in Rule 501(b) of Regulation D under the Securities Act of 1933, as amended (the
"Securities Act"), an "Affiliate") of the Company has, directly, or through any agent, (i) sold,
offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which is or will be integrated with the sale of the Shares in a manner
that would require the registration under the Securities Act of the Shares; or (ii) offered, solicited offers to buy or sold the Shares by any form of general solicitation or general
advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of 

the Securities Act; and the Company will not, and will instruct its Affiliates not to, engage in any of the actions described in clauses (i) and (ii) of this paragraph. 

    (q) Subject
to the accuracy of the Purchaser's representations herein, it is not necessary in connection with the offer, sale and delivery of the Shares to the
Purchasers in the manner contemplated by this Agreement to register the Shares under the Securities Act. 

    (r) The
Company shall comply with all requirements of the National Association of Securities Dealers, Inc. with respect to the issuance of the Shares and the
listing thereof on The Nasdaq National Market. 

    (s) The
Company has not taken and will not, in violation of applicable law, take, any action designed to or that might reasonably be expected to cause or result in
stabilization or manipulation of the price of the Common Stock to facilitate the sale or resale of the Shares. 

    (t)  The
Company is eligible to file a registration statement on Form S-3. 

    (u) The
Company shall, as soon as practicable following the execution of this and any other Agreements, publicly disclose the sale of Shares pursuant to such Agreements
to the extent required by the Exchange Act and the applicable rules and regulations of the Commission thereunder; provided that, except as required by law, including specifically the rules,
regulations and disclosure requirements under the Securities Act and Exchange Act, no disclosure will be made identifying the Purchaser. 

    7.  Representations, Warranties and Covenants of the Purchaser.

    The
Purchaser represents and warrants to, and covenants with, the Company that: 

    (a) The
Purchaser is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a "QIB")
and has requested, received, reviewed and considered all information it deems relevant in making an informed decision to purchase the Shares. 

    (b) The
Purchaser is acquiring the number of Shares set forth on the signature page hereto in the ordinary course of its business and for its own account for investment
only and with no present intention of distributing any of such Shares or any arrangement or understanding with any other persons regarding the distribution of such Shares, other than as contemplated
in Section 8 of this Agreement. 

    (c) The
Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit offers to buy, purchase or otherwise acquire or
take a pledge of) any of the Shares, except in compliance with the Securities Act and the applicable rules and regulations of the Commission thereunder. 

    (d) The
Purchaser will have, on or prior to the Closing Date, furnished to the Company a fully completed Selling Stockholder Questionnaire attached as Appendix I
hereto for use in preparation of the Registration Statement and all of the information contained therein will be true and correct as of the Closing Date. 

    (e) The
Purchaser will notify the Company immediately of any change in any such information until such time as the Purchaser has sold all of its Shares or until the
Company is no longer required to keep the Registration Statement effective. 

    (f)  In
connection with its decision to purchase the number of Shares set forth on the signature page hereto, the Purchaser (i) has relied only upon the Exchange
Act Documents, the representations and warranties of the Company contained herein and the information received pursuant to Section 7(a), and (ii) has not relied on any information or
advice furnished by or on behalf of Morgan Stanley & Co. Incorporated. 

    (g) The
Purchaser will not make any sale of the Shares without complying with the provisions of this Agreement and without causing the prospectus delivery requirement
under the Securities Act to be satisfied, and the Purchaser acknowledges that the certificates evidencing the Shares will 

be imprinted with a legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for the Shares): 

"THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT UNTIL THE PASSAGE OF TWO YEARS FROM MAY 14, 2001, PROVIDED PURCHASER IS NOT AN AFFILIATE OF THE COMPANY, UNLESS THE SECURITIES ARE
OTHERWISE SOLD, TRANSFERRED OR ASSIGNED IN COMPLIANCE WITH ALL APPLICABLE SECURITIES LAWS." 

The
Purchaser acknowledges that there may occasionally be times when the Company determines that it must suspend the use of the Prospectus (as defined in Section 11(a)) forming part of the
Registration Statement, as set forth in Section 10. 

    (h) The
Purchaser will notify the Company promptly of the sale of any of its Shares, other than (i) sales pursuant to a Registration Statement contemplated in
Section 8 of this Agreement and (ii) sales following termination of the transfer restrictions pursuant to Section 12, and the Purchaser will furnish any information reasonably
requested by the Company, including an opinion of counsel reasonably satisfactory to the Company, to evidence the exemption from the registration requirements of the Securities Act, the applicable
rules and regulations of the Commission thereunder, and state securities laws, in reliance upon which such sales have been made. 

    (i)  This
Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Purchaser, enforceable in accordance with its
terms, subject to applicable bankruptcy, insolvency or similar laws affecting creditors' rights generally and general principles of equity and except as rights to indemnification and contribution in
Section 11 hereof may be limited under applicable law. 

    (j)  The
Purchaser will not, prior to the effectiveness of the Registration Statement, if then prohibited by law or regulation, sell, offer to sell, solicit offers to
buy, dispose of, loan, pledge or grant any right with respect to (collectively, a "Disposition"), the Common Stock, nor will the Purchaser engage in any
hedging or other transaction which is designed or could reasonably be expected to lead to or result in a Disposition of Common Stock by the Purchaser or any person or entity. Such prohibited hedging
or other transaction would include, without limitation, effecting any short sale or having in effect a short position (whether such short sale or position is against the box and regardless of when
such position was entered into) or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to the Common Stock or with respect to any security
(other than a broad-based market basket or index) that includes or derives any significant part of its value from the Common Stock. 

    (k) The
Purchaser will hold in confidence all information concerning this Agreement and the placement of shares hereunder until the earlier of such time as the Company
has made a public announcement concerning the Agreement and the placement of shares hereunder or this Agreement is terminated. 

    8.  Shelf Registration. The Company shall: 

    (a) use
its best efforts to prepare and file or cause to be prepared and filed with the Commission as soon as practicable but in any event by the date (the
"Filing Deadline Date") ten (10) days after the Closing Date, a registration statement (the "Registration
Statement") registering the resale from time to time by the Purchaser of all of the Shares. The Registration Statement shall be on Form S-3 or another
appropriate form permitting registration of such Shares for resale by the Purchaser from time to time through the automated quotation system of The Nasdaq National Market or the facilities of a
national security exchange on which the Common Stock is then traded, or in privately negotiated transactions. The Company shall use its reasonable efforts, subject to receipt of necessary information
from the Purchaser, to cause the Registration Statement to be declared effective under the Securities Act as promptly as is practicable but in any 

event by the date (the "Effectiveness Deadline Date") that is ninety (90) days after the date the Registration Statement is filed. 

    (b) Use
all commercially reasonable efforts to prepare and file with the Commission such amendments and post-effective amendments to the Registration
Statement as may be necessary to keep such Registration Statement continuously effective for a period not to exceed the earlier of (i) the second anniversary of the Closing Date, or
(ii) such time as all Shares purchased by such Purchaser pursuant to this Agreement have been sold pursuant to a registration statement or pursuant to Rule 144 under the Securities Act
(such period, the "Effectiveness Period"); cause the related prospectus to be supplemented by any required Prospectus supplement, and as so supplemented
to be filed pursuant to Rule 424 (or any similar provisions then in force) under the Securities Act; and use its best efforts to comply with the provisions of the Securities Act applicable to
it with respect to the disposition of all securities covered by such Registration Statement during the Effectiveness Period in accordance with the intended methods of disposition by the sellers
thereof set forth in such Registration Statement as so amended or such Prospectus as so supplemented. 

    (c) As
promptly as practicable give notice to the Purchaser (i) when any Prospectus, Prospectus supplement or the Registration Statement or a
post-effective amendment to the Registration Statement has been filed with the Commission and, with respect to a Registration Statement or any post-effective amendment, when
the same has been declared effective. 

    (d) Use
reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of the Registration Statement or the lifting of any suspension of the
qualification (or exemption from qualification) of any of the Shares for sale in any jurisdiction in which they have been qualified for sale, in either case at the earliest possible moment, and
provide prompt notice to the Purchaser of the withdrawal of any such order. 

    (e) During
the Effectiveness Period, deliver to the Purchaser in connection with any sale by the Purchaser of Shares pursuant to the Registration Statement, without
charge, as many copies of the Prospectus or Prospectuses relating to such Shares (including each preliminary prospectus) and any amendment or supplement thereto as such the Purchaser may reasonably
request. 

    (f)  File
documents required of the Company for customary Blue Sky clearance in states specified in writing by the Purchaser; provided that the Company will not be
required to (i) qualify as a foreign
corporation or as a dealer in securities in any jurisdiction where it would not otherwise be required to qualify but for this Agreement or (ii) take any action that would subject it to general
service of process in suits or to taxation in any such jurisdiction where it is not then so subject. 

    (g) Bear
all fees and expenses incurred in connection with the performance by the Company of its obligations under paragraphs (a) through (f) of this
Section whether or not the Registration Statement is declared effective, other than fees and expenses, if any, of counsel or other advisors to the Purchaser or underwriting discounts, brokerage fees
and commissions incurred by the Purchaser. 

    (h) Not
allow any stockholders other than the Purchaser to include its shares in the Registration Statement. 

    9.  Delay in Filing or Effectiveness of Registration Statement. If the Registration Statement is not filed by the
Company with the Commission on or prior to the Filing Deadline Date, then for each day following the Filing Deadline Date, until but excluding the date the Registration Statement is filed, or if the
Registration Statement is not declared effective by the Commission by the Effectiveness Deadline Date, then for each day following the Effectiveness Deadline Date, until but excluding the date the
Commission declares the Registration Statement effective, the Company shall, for each such day, pay the Purchaser, as liquidated damages and not as a penalty, an amount equal to 0.15% of the Purchase
Price per week; and for any such day, such payment shall be made no later than the first business day of the calendar month next succeeding the month in which such day occurs. 

    The parties agree that the sole damages payable for a violation of the terms of this Agreement with respect to which liquidated damages are expressly provided shall be such liquidated
damages. Nothing shall preclude the Purchaser from pursuing or obtaining specific performance or other equitable relief with respect to this Agreement. 

    The
parties hereto agree that the liquidated damages provided for in this Section 9 constitute a reasonable estimate of the damages that may be incurred by the Purchaser by
reason of the failure of the Registration Statement to be filed or declared effective in accordance with the provisions hereof. 

    10. Transfer of Shares After Registration; Suspension.

    (a) The
Purchaser agrees that it will not effect any disposition of the Shares or its right to purchase the Shares that would constitute a sale within the meaning of
the Securities Act except as contemplated in
the Registration Statement referred to in Section 8(a) and as described below or as otherwise permitted by law, and that it will promptly notify the Company of any changes in the information
set forth in the Registration Statement regarding the Purchaser or its plan of distribution. 

    (b) The
Company shall, as promptly as practicable, give notice to the Purchaser (i) of any request, following the effectiveness of the Registration Statement
under the Securities Act, by the Commission or any other federal or state governmental authority for amendments or supplements to any Registration Statement or related prospectus or for additional
information, (ii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the
initiation or threatening of any proceedings for that purpose, (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, (iv) of the occurrence of a Material Event (as defined in
Section 10(c)) and (v) of the determination by the Company that a post-effective amendment to a Registration Statement will be filed with the Commission, which notice may, at
the discretion of the Company (or as required pursuant to paragraph 10(c)), state that it constitutes a Deferral Notice, in which event the provisions of Section 10(c) shall apply. 

    (c) The
Company shall, upon (A) the issuance by the Commission of a stop order suspending the effectiveness of the Registration Statement or the initiation of
proceedings with respect to the Registration Statement under Section 8(d) or 8(e) of the Securities Act, (B) the occurrence of any event or the existence of any fact (a
"Material Event") as a result of which the Registration Statement shall contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein not misleading, or the related prospectus shall contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or (C) the occurrence or
existence of any pending corporate development that, in the reasonable discretion of the Company, makes it appropriate to suspend the availability of the Registration Statement and the related
Prospectus, (i) in the case of clause (B) above, subject to the next sentence, as promptly as practicable prepare and file, if necessary pursuant to applicable law, a
post-effective amendment to such Registration Statement or a supplement to the related Prospectus or any document incorporated therein by reference or file any other required document that
would be incorporated by reference into such Registration Statement and Prospectus so that such Registration Statement does not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading, and such prospectus does not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, as thereafter delivered to
the purchasers of the Shares being sold thereunder, and, in the case of a post-effective amendment to the Registration Statement, subject to the next sentence, use its reasonable efforts
to cause it to be declared effective as promptly as is practicable, and (ii) give notice to the Purchaser that the 

availability of the Registration Statement is suspended (a "Deferral Notice") and, upon receipt of any Deferral Notice, the Purchaser agrees not to sell
any Shares pursuant to the Registration Statement until such Purchaser's receipt of copies of the supplemented or amended prospectus provided for in
clause (i) above, or until it is advised in writing by the Company that the Prospectus may be used, and has received copies of any additional or supplemental filings that are incorporated or
deemed incorporated by reference in such Prospectus. The Company will use all reasonable efforts to ensure that the use of the Prospectus may be resumed (x) in the case of clause (A) and
(B) above, as promptly as is practicable, and (y) in the case of clause (C) above, as soon as, in the sole judgment of the Company, public disclosure of such Material Event would
not be prejudicial to or contrary to the interests of the Company or, if necessary to avoid unreasonable burden or expense, as soon as practicable thereafter. The Company shall be entitled to exercise
its right under this Section 10(c) to suspend the availability of the Registration Statement or any Prospectus no more than four (4) times in any twelve-month period, and any such period
during which the availability of the Registration Statement and any Prospectus is suspended (the "Deferral Period") shall not exceed thirty
(30) days. The period of any such Deferral Period shall be added to the period of time the Company has agreed to keep the Registration Statement effective. The Company shall use all
commercially reasonable efforts to limit the duration and number of any Deferral Periods. The Purchaser hereby agrees that upon receipt of any Deferral Notice from the Company, the Purchaser shall,
and shall cause each of its officers, directors, employees, affiliates, advisors, agents and representatives to, keep confidential all nonpublic information set forth in such notice including the
existence or terms of such Deferral Notice. 

    11. Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless the Purchaser and each
person, if any, who controls the Purchaser within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims,
damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement or the prospectus included in the Registration Statement, as amended or supplemented by any amendment
or prospectus supplement, including post-effective amendments, and including all material incorporated by reference in such prospectus (the
"Prospectus") or in any amendment or supplement thereto or in any preliminary prospectus, or caused by any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by (i) any
such untrue statement or omission or alleged untrue statement or omission based upon information relating to the Purchaser furnished to the Company in writing by such Purchaser expressly for use
therein, or (ii) the failure of such Purchaser to comply with the covenants and agreements contained in Sections 7 and 10 hereof respecting resale of the Shares. 

    (b) The
Purchaser agrees to indemnify and hold harmless the Company, its directors and its officers and each person, if any, who controls the Company within the meaning
of either Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, any
legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim), insofar as such losses, claims, damages or liabilities are caused by (i) the
failure of the Purchaser to comply with the covenants and agreements contained in Sections 7 and 10 hereof respecting resale of the Shares, (ii) any untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement or the Prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or caused by any omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue
statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with information relating to the Purchaser furnished in writing by the Purchaser to
the Company expressly for use in the Registration Statement or Prospectus. 

    (c) In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to
Section 11(a) or 11(b), such person (the "indemnified party") shall promptly notify the person against whom such indemnity may be sought (the
"indemnifying party") in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the
indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such
proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party
unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any
impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in
the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all indemnified parties, and that all such fees and expenses shall be
reimbursed as they are incurred. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a
final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying
party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are
the subject matter of such proceeding. 

    (d) To
the extent that the indemnification provided for under Section 11(a) or 11(b) is unavailable to an indemnified party or is insufficient in respect of any
losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount
paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the
indemnifying party or parties on the one hand and the indemnified party or parties on the other hand or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the indemnifying party or parties on the one
hand and of the indemnified party or parties on the other hand in connection with the statements or omissions or other matters that resulted in such losses, claims, damages or liabilities, as well as
any other relevant equitable considerations. The relative benefits received by the Company shall be deemed to be equal to the total net proceeds from the sale pursuant to the Purchase Agreement
(before deducting expenses and after deducting all placement agent fees) of the Shares to which such losses, claims, damages or liabilities relate. The relative benefits received by the Purchaser
shall be deemed to be equal to the value of receiving Shares that are registered under the Securities Act. The relative fault of the Purchaser on the one hand and the Company on the other hand shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact, or the inaccurate or
the alleged inaccurate representation or warranty relates to information supplied by the Purchaser or by the Company and the parties' relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission. 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 11(d) were determined by pro rata allocation or by any other method or allocation that
does not take account of the equitable considerations referred to in the immediately preceding paragraph. The amount paid or payable by an indemnified party as a 

result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other
expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding this Section 11(d), the Purchaser shall not be
required to contribute any amount in excess of the amount by which the net amount received by the Purchaser from the sale of the Shares to which such loss relates exceeds the amount of any damages
that such indemnifying party has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

    (e) The
remedies provided for in this Section 11 are not exclusive and shall not limit any rights or remedies that may otherwise be available to any indemnified
party at law or equity. 

    (f)  The
indemnity and contribution provisions contained in this Section 11 and the representations, warranties and other statements of the Company and the
Purchaser contained in this Agreement shall survive the execution of this Agreement and shall remain operative and in full force and effect regardless of (i) any investigation made by or on
behalf of the Purchaser or any person controlling the Purchaser, or the Company, or the Company's officers or directors or any person controlling the Company and (ii) the sale of any Shares by
the Purchaser. 

    12. Termination of Conditions and Obligations. The conditions precedent imposed by Sections 7, 8 and 10 upon the
transferability of the Shares shall cease and terminate as to any particular number of the Shares (and any legend on the Shares will be removed by the Company) at such time as such Shares have been
effectively registered under the Securities Act and sold or otherwise disposed of in accordance with the intended method of disposition set forth in the Registration Statement covering such Shares,
upon the passage of two years from the Closing Date, or at such time as an opinion of counsel satisfactory to the Company shall have been rendered to the effect that such conditions are not necessary
in order to comply with the Securities Act. 

    13. Information Available. So long as the Registration Statement is effective covering the resale of Shares owned by the
Purchaser, the Company will furnish or make available to the Purchaser: 

    (a) as
soon as practicable after it is available (but in the case of the Company's Annual Report to Stockholders, within 90 days of each fiscal year of the
Company), one copy of: 

     (i) its
Annual Report to Stockholders (which Annual Report shall contain financial statements audited in accordance with generally accepted accounting principles by a
national firm of certified public accountants); 

    (ii) if
not included in substance in the Annual Report to Stockholders, its Annual Report on Form 10-K; 

    (iii) its
Quarterly Reports on Form 10-Q; and 

    (iv) a
full copy of the particular Registration Statement covering the Shares (the foregoing, in each case, excluding exhibits unless specifically requested); and 

    (b) upon
the reasonable request of the Purchaser, an adequate number of copies of the Prospectus to supply to any other party requiring such Prospectus. 

    14. Placement Agent's Fee. The Purchaser acknowledges that the Company intends to pay to Morgan Stanley & Co.
Incorporated, in its capacity as the placement agent for the Shares, a fee in respect of the sale of the Shares to the Purchaser. Each of the parties to this Agreement hereby represents that, on the
basis of any actions and agreements by it, there are no other brokers or finders entitled to compensation in connection with the sale of the Shares to the Purchaser. 

    15. Rule 144. (a) The Company covenants that, if at any time before the end of the Effectiveness Period
the Company is not subject to the reporting requirements of the Exchange Act, it will cooperate 

with the Purchaser and take such further reasonable action as the Purchaser may reasonably request in writing (including, without limitation, making such reasonable representations as the Purchaser
may reasonably request), all to the extent required from time to time to enable the Purchaser to sell Shares without registration under the Securities Act within the limitation of the exemptions
provided by Rule 144 under the Securities Act and customarily taken in connection with sales pursuant to such exemptions. Upon the written request of the Purchaser, the Company shall deliver to
the Purchaser a written statement as to whether it has complied with such reporting requirements, unless such a statement has been included in the Company's most recent report filed pursuant to
Section 13 or Section 15(d) of Exchange Act. Notwithstanding the foregoing, nothing in this Section 14 shall be
deemed to require the Company to register any of its securities (other than the Common Stock) under any section of the Exchange Act. 

    (b) The
Company shall file the reports required to be filed by it under the Exchange Act and shall comply with all other requirements set forth in the instructions to
Form S-3 in order to allow the Company to be eligible to file registration statements on Form S-3. 

    16. Notices. All notices and other communications provided for or permitted hereunder shall be made in writing by hand
delivery, by telecopier, by courier guaranteeing overnight delivery or by first-class mail, return receipt requested, and shall be deemed given (i) when made, if made by hand delivery,
(ii) upon confirmation, if made by telecopier, (iii) one (1) business day after being deposited with such courier, if made by overnight courier or (iv) on the date
indicated on the notice of receipt, if made by first-class mail, to the parties as follows: 

    (a) if
to the Purchaser, at its address on the signature page hereto; 

    (b) if
to the Company, to: 

Cerus
Corporation

Suite 300

2525 Stanwell Drive

Concord, California 94520

Attn: Vice President, Legal Affairs 

with
a copy to: 

Andrea
Vachss, Esq.

Cooley Godward LLP

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306

Fax: (650) 849-7400 

or
to such other address as such person may have furnished to the other persons identified in this Section 16 in writing in accordance herewith. 

    17. Severability. If any term provision, covenant or restriction of this Agreement is held to be invalid, illegal, void
or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated
thereby, and the parties hereto shall use their best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction, it being intended that all of the rights and privileges of the parties shall be enforceable to the fullest extent permitted by law. 

    18. Modification; Amendment. The provisions of this Agreement, including the provisions of this sentence, may not be
amended, modified or supplemented unless pursuant to an instrument in writing signed by the Company and the Purchaser. 

    19. Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and is intended
to be a complete and exclusive statement of the agreement and understanding of the parties hereto with respect to the subject matter contained herein. Except as provided in this Agreement, there are
no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein, with respect to such matters. This Agreement supersedes all prior agreements and undertakings
among the parties with respect to such matters. No party hereto shall have any rights, duties or obligations other than those specifically set forth in this Agreement. 

    20. Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be an original, with
the same effect as if the signatures thereto and hereto were upon the same instrument. 

    21. Applicable Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State
of New York 

    22. Headings. The headings of the sections of this Agreement have been inserted for convenience of reference only and
shall not be deemed a part of this Agreement. 

    IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 

	 	 	DWS Investment GmbH
	

 	
 	

By:	
 	

/s/ Chi Tran Brandli
	

 	
 	

 	
 	

Name: Chi Tran Brandli
	

 	
 	

 	
 	

Title: AVP, Fund Manager Equities
	

 	
 	

 	
 	

Address:	
 	

Gruneburgweg 113-115

D-60612 Frankfurt A.M.

Germany
	

 	
 	

 	
 	

Number of Shares: 1,000,000
	

 	
 	

 	
 	

Aggregate Purchase Price: U.S. $52 Million
	

 	
 	

 	
 	

Tax ID No.:

	

 	
 	

 	
 	

Contact Name:

	

 	
 	

 	
 	

Telephone:

	

 	
 	

 	
 	

Name in which the Shares should be registered (if different):
	

 	
 	

 	
 	

	

 	
 	

 	
 	

Relationship between the Purchaser and the person or entity in whose name the Shares should be registered (if different):
	

 	
 	

 	
 	

	

Agreed to and Accepted by:	
 	

 	
 	

 	
 	

 
	

 	
 	

CERUS CORPORATION
	

 	
 	

By:	
 	

/s/ Stephen T. Isaacs

Name: Stephen T. Isaacs

Title: Chief Executive Officer

EXHIBIT A  

 
 

OPINION OF COUNSEL FOR THE COMPANY    
  

    The opinion of the counsel for the Company, to be delivered pursuant to Section 5(b) of the Purchase Agreement shall be to the effect that: 

    (A) The
Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the
corporate power and authority to own its property and to conduct its business as currently conducted and as described in the Exchange Act Documents and is duly qualified to transact business and is in
good standing in California and, to such counsel's knowledge, in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to
the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company. 

    (B) The
Purchase Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its
terms, subject to applicable bankruptcy, insolvency or similar laws affecting creditors' rights generally and general principles of equity and except as rights to indemnification and contribution in
Section 11 thereof may be limited under applicable law. 

    (C) The
authorized capital stock of the Company conforms as to legal matters to the description (i) of the Common Stock contained in the Company's registration
statement on Form 8-A, filed with the Commission on January 8, 1997 and (ii) of the preferred stock contained in the certificates of designation filed with the
Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998. 

    (D) The
shares of common stock outstanding on the last business date immediately preceding the Closing Date have been duly authorized and are validly issued, fully paid
and non-assessable. 

    (E) The
Shares have been duly authorized and, when issued and delivered in accordance with the terms of the Purchase Agreement, will be validly issued, fully paid and
non-assessable, and the issuance of such Shares will not be subject to any preemptive or similar rights. 

    (F) Based
upon the representations, warranties and agreements of the Purchaser in Section 7 of the Purchase Agreement, it is not necessary in connection with the
offer, sale and delivery of the Shares to the Purchaser under the Purchase Agreement to register the Shares under the Securities Act, it being understood that no opinion is expressed as to any
subsequent resale of any Shares. 

QuickLinks

PURCHASE AGREEMENT

OPINION OF COUNSEL FOR THE COMPANY

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]